Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Adicet Bio Inc Is A Clinical-Stage Biotechnology Company Discovering And Developing Allogeneic Gamma Delta T Cell Therapies For Autoimmune Diseases And Cancer. It Is Advancing A Pipeline Of Off-The-Shelf Gamma Delta T Cells, Engineered With Chimeric Antigen Receptors (Cars), To Facilitate Durable Activity In Patients. The Company'S Main Product Candidate, Prulacabtagene Leucel (Prula-Cel), Is An Allogeneic Gamma Delta T Cell Therapy Expressing A Car Targeting Cd20, And Is Being Developed For The Potential Treatment Of Autoimmune Diseases. Additionally, It Is Pursuing Adi-212, A Next-Generation Gene-Edited And Armored Clinical Candidate Designed To Target Prostate-Specific Membrane Antigen (Psma).